Claraphi Advisory Network’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-852
Closed -$595K 303
2022
Q1
$595K Sell
852
-258
-23% -$163K 0.17% 127
2021
Q4
$701K Sell
1,110
-122
-10% -$75K 0.24% 99
2021
Q3
$745K Sell
1,232
-1,169
-49% -$726K 0.26% 86
2021
Q2
$1.34M Buy
2,401
+31
+1% +$15.7K 0.4% 41
2021
Q1
$1.12M Buy
+2,370
New +$1.15M 0.31% 68
2020
Q2
Sell
-924
Closed -$451K 982
2020
Q1
$451K Buy
+924
New +$381K 0.21% 92

Other funds holding REGN

Claraphi Advisory Network's REGN Position: Q2 2022 in Review

Claraphi Advisory Network sold out of Regeneron Pharmaceuticals (REGN) in Q2 2022, closing a stake of 852 shares — an estimated $595K sold.

Claraphi Advisory Network first reported a position in REGN in Q1 2020 and held it in 6 quarters. The position peaked at $1.34M in Q2 2021. 1,064 funds tracked by Wall St. Rank hold REGN as of Q2 2022.

  • Claraphi Advisory Network reported no remaining Regeneron Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Claraphi Advisory Network sold 852 Regeneron Pharmaceuticals shares in Q2 2022, an estimated $595K.
  • Claraphi Advisory Network first reported a position in Regeneron Pharmaceuticals in Q1 2020 and held it in 6 quarters.
  • Claraphi Advisory Network's Regeneron Pharmaceuticals position peaked at $1.34M in Q2 2021.
  • 1,064 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2022.

Based on Claraphi Advisory Network's 13F filing for Q2 2022, filed 19 Jul 2022.